abstract. Clomiphene citrate (CC) is known to possess dual actions as an estrogen agonist and an estrogen antagonist. To see how the dual actions of CC are exerted through estrogen receptor α (ERα) and/or ERβ we developed a cell-based transcription assay system in which 293T cells were transfected with the luciferase reporter plasmid with estrogen responsive element and either human ERα or ERβ expression plasmid. CC at lower doses (10 -10 M and 10 -12 M), but not higher doses (10 -6 M and 10 -8 M) elicited estrogenic activity via ERα. However, CC at concentrations between 10 -6 M and 10 -12 M did not elicit any estrogenic activity via ERβ. In the presence of 17β-estradiol (E2), CC behaved either as an agonist or as an antagonist via ERα depending on the concentrations of E2, i.e., antagonistic when combined with the higher E2 concentrations, agonistic with the lower E2 concentrations. On the other hand, via ERβ, CC acted as an estrogen antagonist regardless of the concentration of E2 added together. In conclusion, CC acts as an estrogen agonist/antagonist via ERα in a coexisting estrogen concentration-dependent way whereas it acts as an estrogen antagonist via ERβ whether or not estrogen is present.
Key words: Chlomiphene citrate, Estrogen receptor transcription [4] . ER had been assumed to exist as a single species until a novel estrogen receptor was isolated [5] . The classical ER was renamed ERα and the newly identified ER was named ERβ. ERβ has a high degree of sequence homology with the classical estrogen receptor. Interestingly, ERβ is detected in many tissues, including those previously assumed to be estrogen insensitive. In tissues where both ERs are expressed, such as the uterus, mammary glands, and immune system, ERα promotes proliferation whereas ERβ has pro-apoptotic and pro-differentiating functions [5] .
Given that CC is clinically used, it is important to know its behavior in the presence of physiological levels of estrogen. In this study, we evaluated both the estrogenic activity of CC via ERα and ERβ, separately, using 293T cells transfected with either human ERα or ERβ, and the anti-estrogenic activity of CC in the same system in the presence of varying concentrations of 17β-estradiol (E2). original pression vector, human ERβ expression vector, or pCXN2 vector and were resuspended in lysis buffer (PBS, 1% Nonidet P-40, 1 mM EDTA) containing protease inhibitors to prepare whole-cell extracts. The protein concentrations were determined with BioRad Protein Assay reagents (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Whole-cell extracts (10 µg of each sample) were used for Western blot analysis. Proteins were loaded onto 10% SDS-PAGE gels and then transferred to Immobilon polyvinylidene difluoride membranes (Millipore Corp, Bedford, MA, USA). Western blot analysis was carried out using the following primary antibodies: anti-ERα (1:100; sc-53492, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-ERβ (1:100; sc-8974 Santa Cruz Biotechnology), and anti-β-actin (1:3000; A5316 Sigma). Immunoreactive bands of ERα and ERβ were visualized with horseradish peroxidase-conjugated anti-rabbit IgG (1:3000; Santa Cruz Biotechnology). β-actin immunoreactive bands were visualized with horseradish peroxidase-conjugated anti-mouse IgG (1:3000; Santa Cruz Biotechnology). The ECL Plus western blotting system was used to detect antibody protein complexes (Amersham Biosciences).
Statistical analysis
The results are presented as the mean ± SD. The analysis was conducted by one-way analysis of variance (ANOVA). Statistical significance was accepted at P < 0.05.
results
The expression of ERα and ERβ protein was comfirmed by Western blot analysis (Fig. 1 ). CC at concentrations of 10 -10 and 10 -12 M elicited estrogenic activity in cells transfected with ERα; the activity was 30% of that observed using 10 -10 M E2 ( Fig. 2A) . Interestingly, CC at higher doses (10 -6 or 10 -8 M) did not elicit any estrogenic activity. In cells transfected with ERβ however, CC at any concentration between 10 -12 and 10 -6 M did not produce estrogenic activity (Fig. 2B ).
Fig . 3A shows the transcriptional activity of CC in combination with E2 via ERα. CC at 10 -8 and 10 -10 M did not affect the 10 -8 M E2-induced activation of the luciferase activity, indicating that there was no antagonistic activity under these conditions. The addition of CC at either 10 -8 or 10 -10 M in combination with E2 at materials and methods
Plasmid construction
The ERα cDNA originating from HEG0 [6] was cloned into the pCXN2 expression vector [7] to construct a human ERα expression vector [8] . The reverse transcription polymerase chain reaction (RT-PCR) product of ERβ cDNA was cloned into pCXN2 to construct a human ERβ expression vector [8] . The oligonucleotide containing the wild-type ERE of the Xenopus vitellogenin gene A2 enhancer was synthesized and inserted at the upstream position of a reporter plasmid of luciferase assay [9] . The expression vector of sea pansy luciferase was used as an internal control (Picagene; dual luciferase assay kit, Toyo Inc).
Cell culture and luciferase assay
17β-estradiol (E2) and CC were obtained from Sigma Chemical Company and dissolved with ethanol in a 1.5 mL microreaction tube and diluted with cell culture medium to yield indicated final concentrations. The concentration of ethanol in the culture medium was kept at 0.1%.
293T cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal calf serum (GIBCO). 293T cells were transfected with either human ERα or ERβ expression vector, a luciferase reporter plasmid and plasmid with luciferase of sea pansy for the internal control as described previously [10] . One hour before transfection, cell culture medium was replaced with phenol red-free Dulbecco's modified Eagle's medium (GIBCO) containing 10% dextrancoated charcoal treated fetal bovine serum (HyClone, Cat. No. SH30068). 1 × 10 6 of 293T cells were used. Cells were transfected with 2 µg of reporter plasmids and 2 µg of sea pansy luciferase plasmid. After 12 h of incubation, the cells were cultured further with or without 10 -8 , 10 -10 , 10 -12 and 10 -14 M E2 or with 10 -6 , 10 -8 , 10 -10 and 10 -12 M of CC for 24 h. Cell extracts were prepared and assayed for luciferase activity following the manufacture's instructions (Picagene; dual luciferase assay kit, Toyo Inc). Luciferase assays were performed using a MicroLumat Plus (PerkinElmer). The activities of luciferase were high enough for experiment. All data were standardized by sea pansy luciferase activity.
Western blot analysis
293T cells were transfected with human ERα ex-trogenic activity regardless of whether CC was added or not (Fig. 3B) .
Discussion
The present study demonstrates that the agonistic effects of CC via ERα are different from those via ERβ. CC at either 10 -10 or 10 -12 M exhibited approximately 30% of the estrogenic activity of that produced by 17β-estradiol at 10 -10 M in ERα-expressing cells, whereas no activity was detected in ERβ-expressing cells. The antagonistic activity of CC was also different via ERα as compared to ERβ. More specifically, CC at 10 M showed estrogen agonist activity in the presence of E2 at 10 -14 M. Compared to the responses in control cultures (fold induction = 1.0), CC at 10 -8 M showed neither estrogen agonist activity in the presence of E2 at 10 -14 M concentration nor estrogen antagonist activity against E2 at 10 -8 M concentration, but partly and completely blocked the agonist activity of 10 -10 and 10 -12 M E2, respectively. In contrast, CC at 10 -10 M showed estrogen agonist activity in the presence of E2 at 10 -14 M, and antagonist activity was only evident in the presence of 10 -10 M E2 (Fig. 3A) . CC is used as an ovulation-inducing agent. However, the one of the problems in the clinical use of CC is its resulting low pregnancy rate [1] . Although the precise mechanisms for this remain to be clarified, insufficient endometrial growth associated with CC is thought to be responsible for the lower pregnancy rates. ERα knockout mice lacking estrogen responsiveness are infertile [13] , whereas mice lacking ERβ are fertile [14] . These findings suggest a pivotal role for ERα in stimulating endometrial growth and thereby supporting pregnancy. It has been reported that ERβ modulates estrogenic function by inhibiting ERα function [15, 16] . Wada-Hiraike et al., analyzed ERβ knockout mice and suggested that ERα is required for adenogenesis and the development of the uterine endometrium, whrereas ERβ plays a role in the differentiation of the endometrium and expression of progesterone receptor [17] . ERβ has been reported to play a role in decidualization in rat uterus [18] . CC is absorbed from the gastrointestinal tract and undergoes enterohepatic recycling. Its half-life in plasma is 5-7 days. CC can be detected in the feces for up to 6 weeks. As latest literature showed that the concentration of CC is around 10 -8 -10 -7 M in women given a therapeutic dose of CC [12] . Our results showed that CC acts as antagonist at such a high concentration via ERα and ERβ. Because half-life of CC is 5-7 days, it is possible that antagonist effect of CC follows during the first menstrual cycle of the off-period. It is also possible that antagonist effect of CC is in particular strong for ERβ. One possible explanation for the low pregnancy rate resulting from the use of CC is that CC inhibits progesterone action in the endometrium by an antagonistic effect via ERβ.
Commercial preparations contain a mixture of two CC isomers [1] . This mixture contains 30%-50% cis-clomiphene (zuclomiphene) and the remainder is trans-clomiphene (enclomiphene). Differential biological activities of the CC isomers have been demonstrated [19, 20] . It would be interesting to know the properties of each isomer separately via ER subtypes. However, since the clinically used CC is a mixture of both isomers, the present study is clinically relevant.
The gap between ovulation and pregnancy rates with CC treatment has been attributed to the anti-estrogen effects described previously [2] . Metformin, aromatase inhibitors, and low-dose FSH are considered to be possible alternatives for replacing CC during treatment [21] . In this study, CC has been shown ERα. In contrast, CC at 10 -8 M completely eliminated the estrogenic activity of E2 at 10 -10 M via ERβ, thus indicating that the antagonistic property of CC is more pronounced via ERβ than ERα. Furthermore, CC at 10 -10 M showed weak estrogen agonist activity in the presence of E2 at 10 -14 M in ERα-expressing cells, but CC did not show estrogen agonistic activity in ERβ-expressing cells. There is little clinical implication at such low concentration of E2. But, the results that we showed in this manuscript about transcriptional activity of ERs treated with CC are useful for understanding a molecular biologic effect of CC via ERs. It is possible that the estrogen agonistic activity of CC may not be observed at high concentrations of E2 via ERα. The serum concentration of CC in women given a therapeutic dose of CC is reported to be 10 -9 -10 -7 M [11, 12] . In view of this, the present results serve to emphasize that CC elicits both estrogen agonistic and antagonistic activities in the usual clinical contexts. tive organs, it would be useful to explore new SERMs, which have effects on the ovary as well as the uterus, to support reproduction.
to possess dual actions, i.e. an estrogen agonist and antagonist, depending on the ER subtype status and the concurrent presence of estradiol. Given the characteristic distribution of ERα and ERβ in the reproducreferences
